"Oxidopamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
| Descriptor ID |
D016627
|
| MeSH Number(s) |
D02.092.311.342.478.650
|
| Concept/Terms |
Oxidopamine- Oxidopamine
- 6-Hydroxydopamine
- 6 Hydroxydopamine
- 6-OHDA
|
Below are MeSH descriptors whose meaning is more general than "Oxidopamine".
Below are MeSH descriptors whose meaning is more specific than "Oxidopamine".
This graph shows the total number of publications written about "Oxidopamine" by people in this website by year, and whether "Oxidopamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxidopamine" by people in Profiles.
-
Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs. Exp Neurol. 2023 10; 368:114509.
-
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
-
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016 10 03; 70:77-84.
-
Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. Neuropsychopharmacology. 2012 May; 37(6):1397-408.
-
Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
-
Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
-
Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions. Brain Struct Funct. 2008 Sep; 213(1-2):197-213.
-
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
-
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006; 15(3):239-50.
-
Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.